Please use this identifier to cite or link to this item:
http://hdl.handle.net/11452/25359
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.date.accessioned | 2022-03-25T13:08:43Z | - |
dc.date.available | 2022-03-25T13:08:43Z | - |
dc.date.issued | 2009-03 | - |
dc.identifier.citation | Kırlı, S. (2009). "Similarities and differences in the mechanism of action of antidepressants". Klinik Psikofarmakoloji Bülteni, 19(Supplement 1), S86-S89. | tr_TR |
dc.identifier.issn | 1017-7833 | - |
dc.identifier.uri | http://hdl.handle.net/11452/25359 | - |
dc.description.abstract | Considering the pathophysiology of depression, we may talk about the alteration of several receptors, enzymes, neurotransmitters or secondary messengers. Current antidepressants are thought to act by restoring these alterations. Despite having different mechanism of actions, antidepressants act on these interconnected systems to increase CREB or BDNF, thus they have a similar effect on the final biological pathway. However, since antidepressants act on different receptors, the time to response and the symptom profile they act on at the beginning of the therapy may differ. Thus it would be rational to consider the symptom profile and desired time to response when choosing among antidepressants with different mechanism of action or switching from one antidepressant to another. | en_US |
dc.language.iso | tr | tr_TR |
dc.publisher | Küre İletişim Grubu | tr_TR |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | MAOI | en_US |
dc.subject | NRI | en_US |
dc.subject | SNRI | en_US |
dc.subject | SSRI | en_US |
dc.subject | TCA | en_US |
dc.subject | Pharmacology & pharmacy | en_US |
dc.subject | Psychiatry | en_US |
dc.title | Similarities and differences in the mechanism of action of antidepressants | en_US |
dc.type | Article | en_US |
dc.identifier.wos | 000209020900017 | tr_TR |
dc.identifier.scopus | 2-s2.0-67650763263 | tr_TR |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | tr_TR |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Psikiyatri Anabilim Dalı. | tr_TR |
dc.identifier.startpage | S86 | tr_TR |
dc.identifier.endpage | S89 | tr_TR |
dc.identifier.volume | 19 | tr_TR |
dc.identifier.issue | Supplement 1 | en_US |
dc.relation.journal | Klinik Psikofarmakoloji Bülteni | tr_TR |
dc.contributor.buuauthor | Kırlı, Selçuk | - |
dc.subject.wos | Pharmacology & pharmacy | en_US |
dc.subject.wos | Psychiatry | en_US |
dc.indexed.wos | SCIE | en_US |
dc.indexed.scopus | Scopus | en_US |
dc.wos.quartile | Q4 | en_US |
dc.contributor.scopusid | 14019745700 | tr_TR |
dc.subject.scopus | Desvenlafaxine; Involutional Depression; Antidepressants | en_US |
dc.subject.emtree | Antidepressant agent | en_US |
dc.subject.emtree | Brain derived neurotrophic factor | en_US |
dc.subject.emtree | Cyclic AMP responsive element binding protein | en_US |
dc.subject.emtree | Dopamine | en_US |
dc.subject.emtree | Monoamine oxidase inhibitor | en_US |
dc.subject.emtree | Noradrenalin | en_US |
dc.subject.emtree | Noradrenalin uptake inhibitor | en_US |
dc.subject.emtree | Serotonin | en_US |
dc.subject.emtree | Serotonin 1A receptor | en_US |
dc.subject.emtree | Serotonin 1B receptor | en_US |
dc.subject.emtree | Serotonin 2 receptor | en_US |
dc.subject.emtree | Serotonin uptake inhibitor | en_US |
dc.subject.emtree | Tianeptine | en_US |
dc.subject.emtree | Tricyclic antidepressant agent | en_US |
dc.subject.emtree | Conference paper | en_US |
dc.subject.emtree | Depression | en_US |
dc.subject.emtree | Dopamine metabolism | en_US |
dc.subject.emtree | Drug mechanism | en_US |
dc.subject.emtree | Pathophysiology | en_US |
dc.subject.emtree | Psychopharmacotherapy | en_US |
dc.subject.emtree | Synapse | en_US |
dc.subject.emtree | Treatment response | en_US |
Appears in Collections: | Scopus Web of Science |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.